Jefferies — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Taysha Gene Therapiestayshagtx.comin𝕏NASDAQ: TSHAJun 2026 · $200M
Taysha Gene Therapies develops and commercializes gene therapies for monogenic diseases of the central nervous system, serving patients with rare and larger CNS conditions.
BiotechDeep TechDigital HealthHealthtechMedical DevicesTexas, US
R.A. Session II(Executive Officer, Director)inSean P. Nolan(Chief Executive Officer and Board Chairman)in
BoardPaul B. Manning(Director)in
Co-investorsGV (Google Ventures)BairdGoldman SachsPBM Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.